Literature DB >> 15201985

Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumors.

D Hunter Best1, Genelle M Butz, Karen Moller, William B Coleman, David B Thomas.   

Abstract

Immature ovarian teratoma is a common germ cell tumor of young women. Patients with immature teratoma often exhibit multiple neoplasms, including tumors outside the ovaries, and occasionally a rare benign condition termed gliomatosis peritonei (GP). These multiple neoplasms are generally believed genetically-linked progeny of the ovarian tumor resulting from local recurrence/spread. In this study, we performed a molecular analysis of a single patient clinically diagnosed with immature ovarian teratoma, GP, and recurrent pelvic mucinous teratoma. Microsatellite PCR and amplicon analysis was performed to genetically characterize tissue samples from omental glial implants and multiple peritoneal tumors. PCR-based amplification of microsatellite markers identifies unique genetic differences (allelic variation) between tumors resulting from divergent natural histories among multiple tumor nodules in a single patient. A total of 21 different microsatellite markers were employed, and seven provided informative results (D3S1744, D6S1056, D7S2846, D14S306, D16S764, D18S858, D22S420). These markers demonstrated mutually exclusive genetic differences among the tumors from this patient, establishing the neoplasms as genetically distinct from each other (non-identical), and that no lineage relationship exists among them. This observation suggests that the multiple tumors arising in this patient with immature ovarian teratoma, GP, and recurrent pelvic mucinous neoplasm represent multiple independent tumors rather than true tumor recurrence/spread. The results of this study suggest strongly that patients with recurrent teratoma may be afflicted with a tumor-prone syndrome where one or more peritoneal cell types or populations are predisposed to neoplastic conversion and formation of tumors as a result of an endogenous or exogenous neoplastic stimuli.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201985

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Gliomatosis peritonei with bilateral ovarian teratomas: A report of two cases.

Authors:  Jiawei Wang; Jingjing Xu; Minming Zhang; Baizhou Li
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

2.  Gliomatosis peritonei is associated with frequent recurrence, but does not affect overall survival in patients with ovarian immature teratoma.

Authors:  Na Ra Yoon; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Insuk Sohn; Chang Ohk Sung; Sang Yong Song
Journal:  Virchows Arch       Date:  2012-07-21       Impact factor: 4.064

3.  [Teratoma of the ovary. Clinical and pathological differences between mature and immature teratomas].

Authors:  D Schmidt; F Kommoss
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

4.  Growing teratoma syndrome and peritoneal gliomatosis.

Authors:  H Mrabti; I El Ghissassi; Y Sbitti; M Amrani; H Hachi; H Errihani
Journal:  Case Rep Med       Date:  2011-04-07

5.  Giant liver teratoma with gliosis peritonei treated by right extended hepatectomy: Overview and case report.

Authors:  Luis Enrique García-Ríos; Ana K García-Ávila; Marisol Luna-Castillo; Jazmín G De Anda-González; Rafael Medrano-Guzmán
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-11-30

Review 6.  Gliomatosis Peritonei and Its Relation to Teratoma: Role of Imaging and Histological Aspects.

Authors:  Tarang Patel; Virendrakumar Meena
Journal:  Cureus       Date:  2022-09-06

7.  Hepatic teratoma and peritoneal gliomatosis: a case report.

Authors:  Christoph Karlo; Sebastian Leschka; Matthias Dettmer; Stefan Breitenstein; Paul Stolzmann
Journal:  Cases J       Date:  2009-12-10

8.  Immature ovarian teratoma with unusual gliomatosis.

Authors:  Ancuta Gheorghisan-Galateanu; Dana Cristina Terzea; Mara Carsote; Catalina Poiana
Journal:  J Ovarian Res       Date:  2013-04-16       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.